ROCKVILLE, Md., May 11, 2017 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage
clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today
announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation for SYN-004
(ribaxamase) for the prevention of Clostridium difficile infection. SYN-004 (ribaxamase) is the Company's first-in-class
oral enzyme designed to protect the gut microbiome from disruption caused by certain intravenous (IV) beta-lactam
antibiotics.
The Breakthrough Therapy Designation is based on data from the successful Phase 2b clinical trial of ribaxamase, which met its
primary endpoint of significantly reducing CDI. FDA Breakthrough Therapy Designation is intended to expedite development and
review timelines when preliminary clinical evidence indicates that a drug may demonstrate substantial improvement on one or more
clinically significant endpoints over available therapies for serious or life threatening diseases. If approved by the FDA,
SYN-004 (ribaxamase) would be the first available drug designed to prevent Clostridium difficile infection by protecting
the gut microbiome from antibiotic-mediated dysbiosis.
"We are delighted by the FDA's recognition of ribaxamase's potential to prevent CDI, and the dire need to fill the current
void of an approved intervention," said Jeffrey Riley, President and Chief Executive Officer.
"Following this announcement, we have been asked and anticipate requesting a Type-B multidisciplinary meeting with the Agency for
a comprehensive discussion on the overarching, high-level drug development plan and pathway to licensure for ribaxamase. We look
forward to working closely with the FDA throughout the development and review process and remain dedicated to bringing this
potentially paradigm-shifting approach to antibiotic therapy to patients in critical need."
About Clostridium difficile Infection
Clostridium difficile infection is the number one hospital acquired infection in the U.S., with more than
453,0001 patients diagnosed annually. CDI results in approximately 29,0001 deaths, $1.5 billion 1 in additional healthcare costs, as well as significant and sometimes prolonged
illness.
About SYN-004 (ribaxamase) and the Phase 2b Study
SYN-004 (ribaxamase) is a first-in-class oral enzyme designed to degrade certain IV beta-lactam antibiotics within the GI
tract and maintain the natural balance of the gut microbiome for the prevention of CDI, pathogenic overgrowth and the emergence
of antimicrobial resistance (AMR). Synthetic Biologics initiated a Phase 2b proof-of-concept clinical trial intended to evaluate
the effectiveness of ribaxamase to prevent the onset of primary C. difficile infection (CDI), antibiotic-associated
diarrhea (AAD) and the emergence of antimicrobial resistance (AMR) in patients hospitalized with a lower respiratory infection
and receiving IV ceftriaxone. Results from this trial indicate that patients receiving ribaxamase achieved a 71.4% relative risk
reduction (p-value=0.045) in CDI rates compared to patients receiving placebo. Analysis of the data also demonstrated a
significant reduction in new colonization by vancomycin-resistant enterococci (VRE) for patients receiving ribaxamase compared to
placebo (p-value=0.0002). Adverse events reported during this trial were comparable between treatment and placebo arms. Analysis
of data from several exploratory endpoints designed to evaluate ribaxamase's ability to prevent the emergence and proliferation
of AMR in the gut microbiome is ongoing.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a late-stage clinical company developing therapeutics that preserve the
microbiome to protect and restore the health of patients. The Company's lead candidates poised for Phase 3 development are: (1)
SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV)
beta-lactam antibiotics for the prevention of C. difficile infection, pathogenic overgrowth and the emergence of
antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut
microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company is also developing
preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage
biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential,"
"continue," "expects," "anticipates," "intends," "plans," "believes," "estimates" and similar expressions and include
statements regarding the potential of ribaxamase to prevent CDI, the anticipated request for a Type-B
multidisciplinary meeting with the Agency for a comprehensive discussion on the overarching, high-level drug development plan and
pathway to licensure for ribaxamase, the intended expedited development of ribaxamase due to Breakthrough Therapy
Designation , the potentially paradigm-shifting approach to antibiotic therapy to patients in critical need,
and the ability of SYN-004 to protect the gut microbiome from the disruption caused by certain intravenous
(IV) beta-lactam antibiotic and the industry data regarding the expected incidence and economic burden of CDI .
These forward-looking statements are based on management's expectations and assumptions as of the date of this press release
and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those set
forth or implied by any forward-looking statements. Important factors that could cause actual results to differ
materially from current expectations include, among others, Synthetic Biologics' product candidates demonstrating safety and
effectiveness, as well as results that are consistent with prior results, Synthetic Biologics' ability to initiate clinical
trials and if initiated, to complete them on time and achieve desired results and benefits, Synthetic Biologics' clinical trials
continuing enrollment as expected, Synthetic Biologics' ability to obtain regulatory approvals for commercialization of product
candidates or to comply with ongoing regulatory requirements, regulatory limitations relating to Synthetic Biologics' ability to
promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace
and the successful development, marketing or sale of Synthetic Biologics' products by competitors that render Synthetic
Biologics' products obsolete or non-competitive, Synthetic Biologics' ability to maintain its license agreements, the continued
maintenance and growth of Synthetic Biologics' patent estate, Synthetic Biologics becoming and remaining profitable,
Synthetic Biologics' ability to establish and maintain collaborations, Synthetic Biologics' ability to
obtain or maintain the capital or grants necessary to fund its research and development activities, a loss of any of Synthetic
Biologics' key scientists or management personnel, and other factors described in Synthetic Biologics'
Annual Report on Form 10-K for the year ended December 31, 2016 and its other filings with the SEC,
including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the
date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this
release on account of new information, future events, or otherwise, excepted as required by law.
1: Leffler DA et al. N Engl J Med 2015; 372: 1539-1548
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/syn-004-ribaxamase-receives-breakthrough-therapy-designation-from-us-food-and-drug-administration-for-prevention-of-clostridium-difficile-infection-300455818.html
SOURCE Synthetic Biologics, Inc.